Epoch Investment Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-1,525
Closed -$233K 236
2026
Q1
$233K Buy
+1,525
New +$234K ﹤0.01% 232
2024
Q4
Sell
-8,352
Closed -$961K 359
2024
Q3
$961K Sell
8,352
-39
-0.5% -$4.42K ﹤0.01% 303
2024
Q2
$893K Sell
8,391
-45
-0.5% -$4.52K ﹤0.01% 316
2024
Q1
$816K Sell
8,436
-24
-0.3% -$2.46K ﹤0.01% 344
2023
Q4
$854K Buy
8,460
+811
+11% +$78.3K ﹤0.01% 348
2023
Q3
$779K Sell
7,649
-281
-4% -$28.5K 0.01% 360
2023
Q2
$800K Sell
7,930
-855
-10% -$85.5K ﹤0.01% 378
2023
Q1
$808K Sell
8,785
-286
-3% -$25K ﹤0.01% 370
2022
Q4
$823K Sell
9,071
-210
-2% -$17.7K ﹤0.01% 355
2022
Q3
$705K Buy
9,281
+111
+1% +$9.2K ﹤0.01% 368
2022
Q2
$775K Buy
9,170
+754
+9% +$66.2K ﹤0.01% 368
2022
Q1
$738K Buy
8,416
+5,140
+157% +$445K ﹤0.01% 381
2021
Q4
$287K Buy
+3,276
New +$272K ﹤0.01% 337
2021
Q3
Sell
-2,276
Closed -$208K 358
2021
Q2
$208K Sell
2,276
-98
-4% -$8.73K ﹤0.01% 340
2021
Q1
$203K Buy
2,374
+149
+7% +$13.4K ﹤0.01% 323
2020
Q4
$210K Buy
+2,225
New +$194K ﹤0.01% 324
2020
Q3
Sell
-3,500
Closed -$306K 305
2020
Q2
$306K Sell
3,500
-391
-10% -$33.8K ﹤0.01% 278
2020
Q1
$321K Sell
3,891
-634
-14% -$56.6K ﹤0.01% 259
2019
Q4
$428K Sell
4,525
-768
-15% -$68.9K ﹤0.01% 280
2019
Q3
$460K Sell
5,293
-211
-4% -$18.9K ﹤0.01% 261
2019
Q2
$503K Sell
5,504
-450
-8% -$38.1K ﹤0.01% 267
2019
Q1
$513K Sell
5,954
-386
-6% -$31K ﹤0.01% 289
2018
Q4
$487K Sell
6,340
-310
-5% -$24.1K ﹤0.01% 284
2018
Q3
$513K Sell
6,650
-887
-12% -$65.6K ﹤0.01% 292
2018
Q2
$510K Sell
7,537
-962
-11% -$66.4K ﹤0.01% 301
2018
Q1
$616K Sell
8,499
-57
-0.7% -$4.34K ﹤0.01% 295
2017
Q4
$644K Sell
8,556
-122
-1% -$9.21K ﹤0.01% 290
2017
Q3
$668K Sell
8,678
-8
-0.1% -$604 ﹤0.01% 289
2017
Q2
$650K Sell
8,686
-522
-6% -$37K ﹤0.01% 286
2017
Q1
$613K Buy
9,208
+2,672
+41% +$178K ﹤0.01% 302
2016
Q4
$427K Sell
6,536
-14,802
-69% -$960K ﹤0.01% 282
2016
Q3
$1.51M Buy
21,338
+9,199
+76% +$670K 0.01% 263
2016
Q2
$897K Sell
12,139
-9,779
-45% -$676K ﹤0.01% 268
2016
Q1
$1.42M Sell
21,918
-6,892
-24% -$469K 0.01% 238
2015
Q4
$2.22M Buy
28,810
+6,419
+29% +$510K 0.01% 216
2015
Q3
$1.84M Buy
+22,391
New +$1.99M 0.01% 206
2015
Q2
Sell
-10,502
Closed -$928K 273
2015
Q1
$928K Sell
10,502
-28,970
-73% -$2.57M ﹤0.01% 231
2014
Q4
$3.28M Sell
39,472
-1,123
-3% -$93.1K 0.01% 213
2014
Q3
$3.42M Buy
40,595
+2,109
+5% +$171K 0.01% 227
2014
Q2
$3.12M Buy
38,486
+1,317
+4% +$104K 0.01% 231
2014
Q1
$2.83M Buy
+37,169
New +$2.71M 0.01% 236
2013
Q4
Sell
-34,528
Closed -$2.37M 269
2013
Q3
$2.37M Buy
34,528
+1,888
+6% +$125K 0.01% 239
2013
Q2
$2.07M Buy
+32,640
New +$2.12M 0.01% 234

Other funds holding NVS

Epoch Investment Partners's NVS Position: Q2 2026 in Review

Epoch Investment Partners sold out of Novartis (NVS) in Q2 2026, closing a stake of 1,525 shares — an estimated $233K sold.

Epoch Investment Partners first reported a position in NVS in Q2 2013 and held it in 43 quarters. The position peaked at $3.42M in Q3 2014. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Epoch Investment Partners reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
  • Epoch Investment Partners sold 1,525 Novartis shares in Q2 2026, an estimated $233K.
  • Epoch Investment Partners first reported a position in Novartis in Q2 2013 and held it in 43 quarters.
  • Epoch Investment Partners's Novartis position peaked at $3.42M in Q3 2014.
  • 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Epoch Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.